Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily Repro-Dose morphine versus MST Continus

European Journal of Clinical Pharmacology

Volumn 55, Issue 8, 1999, Pages 577-581

  Peat, S ^a   Sweet, P ^a   Miah, Y ^a   Barklamb, M ^a   Larsen, U ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Nycomed Pharma ^*  (Denmark)

Author keywords

Chronic pain; Oral morphine; Sustained release

Indexed keywords

DEXTROMORAMIDE; MORPHINE SULFATE; PLACEBO; RELIADOL; REPRO DOSE MORPHINE; UNCLASSIFIED DRUG;

AGED; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; AGED; ANALGESICS, OPIOID; CHRONIC DISEASE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MORPHINE; PAIN; PAIN MEASUREMENT;

EID: 0032831882     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050675     Document Type: Article

References (9)

1. Khjasteh A, Evans W, Reynolds RD, Thomas G, Savarese J (1987) Controlled release oral morphine sulphate in the treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol 5: 956-961
2. McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, et al (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48: 236-244
3. Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner JG, et al (1989) Pharmacokinetics and clinical efficacy of oral morphine solution and controlled release morphine tablets in cancer patients. Cancer 63: 2275-2283
4. Zech DFJ et al (1995) Validation of World Health Organisation Guidelines for cancer pain relief; a 10 year prospective study. Pain 63: 65-76
5. Hoskin PJ, Hanks QW, Aherne GW, Chapman D, Littleton P, et al (1989) The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 27: 499-505
6. Poulain P, Moran RA, Hanks GW, Hoskin PJ, Aherne GW, et al (1990) CSF concentrations of morphine 6 glucuronide after oral administration of morphine. Pain 41: 115-116
7. Portenoy RK, Khan E, Layman RN, et al (1991) Chronic morphine therapy for cancer pain: plasma and CSF morphine and M-6-G concentrations. Neurology 41: 1457-1461
8. Milne RW, Nation RL, Somogyi AA (1996) The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 28: 345-472
9. Miettinen OS (1970) Estimation of relative risk from individual matched series. Biometrics 26: 75-86